Long-term management of schizophrenia combines continuous antipsychotic treatment with structured psychosocial interventions, physical health care, and relapse-prevention planning over many years.  The strategy is individualized, evolving with illness stage, treatment response, and patient preferences. 
 
Core pharmacological strategy
Maintenance antipsychotics: Continuing antipsychotic medication after remission markedly reduces relapse versus discontinuation/placebo, and all major guidelines recommend ongoing maintenance, usually for years and often indefinitely in recurrent illness. 
 
Dose and formulation: Use the minimum effective dose; long‑acting injectables are valuable where adherence is problematic or relapse risk is high. 
 
Treatment‑resistant illness: Clozapine should be introduced promptly after two adequate antipsychotic trials fail, with ongoing monitoring for metabolic, haematological, and cardiovascular adverse effects. 
 
Psychosocial and psychological treatments
Family work: Family interventions, especially structured psychoeducation, significantly reduce relapse and rehospitalization and are among the most effective long‑term psychosocial strategies. 
 
Individual therapies: Cognitive‑behavioural therapy for psychosis, social‑skills training, and cognitive remediation target persistent positive symptoms, social functioning, and cognitive impairment, improving long‑term functional outcomes beyond what medication alone achieves.
 
Relapse prevention and monitoring
Early‑warning plans: Patients and families are taught to recognize prodromal signs (sleep disruption, rising suspiciousness, subtle thought disorder) and have pre‑agreed steps for rapid review and dose adjustment. 
 
Routine outcome monitoring: Regular, structured assessment of symptoms, functioning, side effects, adherence, substance use, and quality of life helps identify non‑response or emerging deterioration so treatment can be adjusted promptly. 
 
Physical health and side‑effect management
Metabolic and cardiovascular risk: From the start, guidelines emphasize systematic monitoring of weight, waist circumference, blood pressure, lipids, and glucose, with active management of obesity, diabetes, and dyslipidaemia. 
 
Minimizing burden: Choice and adjustment of antipsychotics should explicitly balance efficacy against extrapyramidal symptoms, sedation, hyperprolactinaemia, and metabolic effects, as these both harm health and drive non‑adherence. 
 
Recovery, functioning, and duration of treatment
Functional rehabilitation: Supported employment/education, skills training, and community rehabilitation services are central for role recovery, housing stability, and social integration. 
 
Duration/possible reduction: Many clinicians opt for long‑term or indefinite pharmacological maintenance at the lowest effective dose, with any attempt at reduction or discontinuation done very gradually, with intensive monitoring, and generally reserved for carefully selected, stable individuals.
 
Guidelines for Antipsychotic Maintenance durations for Adults
For adults with schizophrenia-spectrum psychosis, most guidelines recommend at least 1–2 years of continuous antipsychotic maintenance after remission, often extending to 3–5 years or longer depending on relapse history and risk.  Beyond the first few years, many experts lean toward long‑term or indefinite low‑dose maintenance in multi‑episode or high‑risk patients, with any taper only in carefully selected, closely monitored cases. 

​First‑episode psychosis
WHO mhGAP and related guidance: continue antipsychotic treatment for a minimum of 7–12 months after full and sustained remission from a first psychotic episode. 
 
Other national guidelines: recommend at least 12–18 months of maintenance after positive‑symptom remission in first‑episode schizophrenia. 
 
Multiple episodes / established schizophrenia
Several guidelines suggest 2–5 years or longer of maintenance after resolution of an acute episode, particularly once there have been multiple relapses. 
 
Some practice guidelines explicitly advise ≥5 years of continuous treatment after the last episode in patients with several exacerbations, and potentially lifelong treatment in those with aggression, suicidality, or high relapse risk.
 
Relapse risk and long‑term continuation
Stopping antipsychotics within 1–2 years after remission is associated with markedly higher relapse rates (up to ~75% within 12–18 months) compared with continued treatment.
 
References
Barlati, S., Nibbio, G. & Vita, A. (2024, Febriuary 15). 37(3):131-139. Evidence-Based Psychosocial Interventions in Schizophrenia: A Critical Review. Current Opinion in Psychiatry.
 
Bighelli, I., Rodolico, A., Garcia-Mieres, H., Pitschel-Walz, G., Hansen, W-P., et al. (2021, November). 8(11):969-980. Psychosocial and Psychological Interventions for Relapse Prevention in Schizophrenia: A Systematic Review and Network Meta-Analysis. The Lancet Psychiatry.
 
Ceraso, A., Lin, J.J., Schneider-Thoma, J., Siafis, S., Tardy, M. et al. (2020, August 11). 2020(8). Maintenance Treatment with Antipsychotic Drugs for Schizophrenia.Cochrane Database Systematic Reviews.
 
Correll, C.U., Rubio, J.M. & Kane, J.M. (2018, June). 17(2):149-160. What is the Risk-Benefit Ratio of Long-Term Antipsychotic Treatment in People with Schizophrenia? World Psychiatry.
 
Emsley, R., Kilian, S. & Phahladira, L. (2016, May). 29(3):224-229. How Long Should Antipsychotic Treatment be Continued After a Single Episode of Schizophrenia? Current Opinion in Psychiatry.
 
Gaebel, W., Stricker, J. & Riesbeck, M. (2020, November). 225; 4-14. The Long-Term Antipsychotic Treatment of Schizophrenia: A Selective Review of Clinical Guidelines and Clinical Case Examples. Schizophrenia Research.
 
Lawrence, R.E. (2022, October 18). 3(1). Antipsychotic Maintenance Treatment for Patients with Schizophrenia: The Need for Placebo-Controlled Trials and the Risk of Paradigm Shifts. Schizophrenia Bulletin Open
 
McCutheon, R.A., Pillinger, T., Varvari, I., Halstead, S., Ayinde, O.O., et al. (2025, May). 12(5):384-394. Integrate: International Guidelines for the Algorithmic Treatment of Schizophrenia. The Lancet Psychiatry.
 
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T. & Teehan, M. (2017, July 13). 62(9):604-616. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Canadian Journal of Psychiatry.
 
Thompson, A., Winsper, C., Marwaha, S., Haynes, J., Alvarez-Jimenez, M., et al. (2018, June 29). Maintenance Antipsychotic Treatment Versus Discontinuation Strategies Following Remission from First Episode Psychosis: Systematic Review.British Journal in Psychiatry Open. 
 
Young, A.S., Niv, N., Chinman, M., Dixon, L., Eisen, S.V., et al. (2010, July 25). 47(2):123-135. Routine Outcomes Monitoring to Support Improving Care for Schizophrenia: Report from the VA Mental Health QUERI. Community Mental Health.

​An at-risk mental state (ARMS) is a clinical condition in which a person has early warning signs that substantially increase the likelihood of developing a psychotic disorder, but full psychosis has not yet emerged. This is often discussed under terms such as “clinical high risk” or “ultra-high risk” for psychosis. An ARMS describes people who have subtle or intermittent psychotic-like experiences (for example, brief or attenuated hallucinations or delusional ideas), plus other risk factors such as functional decline or family history, and who therefore have a much higher than average risk of later transition to a first-episode psychosis. Not everyone with ARMS goes on to develop psychosis, but the risk is high enough that early assessment and intervention are recommended.
 
Typical Common features include:
Attenuated psychotic symptoms: unusual perceptual experiences, suspiciousness, or odd beliefs that are milder, less frequent, or more reality-tested than in full psychosis.
 
Brief limited psychotic episodes that resolve spontaneously within days, with full return to baseline and preserved insight between episodes.
 
Marked recent decline in functioning (social, academic, or occupational), often accompanied by anxiety, depression, or negative symptoms such as withdrawal and reduced motivation.
 
Most specialized early psychosis services conceptualize ARMS using three broad inclusion pathways:
Attenuated psychotic symptoms over weeks to months that are distressing or impairing.
 
Brief, self-remitting psychotic-like episodes (sometimes called BLIPS: brief limited intermittent psychotic symptoms).
 
A combination of genetic risk (first-degree relative with psychosis or schizotypal personality disorder) plus a clear decline in functioning.
 
Risk and prediction
People meeting ARMS/clinical high-risk criteria have a substantially elevated risk of transition to psychosis compared with the general population, with some cohorts showing transition rates of roughly a quarter to a third over the first few years of follow-up. Predictors of higher risk within this group include longer duration of prodromal symptoms, poorer social functioning, cognitive problems (such as poor attention), and having both attenuated symptoms and genetic risk.
 
Why early identification matters
ARMS is important because intervening at this stage can reduce distress, improve functioning, and may delay or prevent transition to a first episode of psychosis in some individuals. Intervention typically focuses on psychoeducation, family work, cognitive–behavioural or other psychotherapy, management of comorbid anxiety/depression, and careful monitoring, with judicious use of medication when indicated.
 
Several specific symptom patterns and related features in people at clinical high risk (at-risk mental state) are associated with a higher chance of later transition to full psychosis:
Positive symptoms and distress
More severe attenuated positive psychotic symptoms (for example, more intense or frequent subthreshold hallucinations, delusional ideas, or suspiciousness) are among the most robust predictors of transition. High distress linked to these attenuated symptoms, along with distress from anxiety and substance use, also increases risk, suggesting that how threatening or uncontrollable the experiences feel is clinically important.
 
Brief psychotic episodes (BLIPS)
Brief Limited Intermittent Psychotic Symptoms (BLIPS) – short-lived psychotic episodes that remit without sustained treatment – carry a particularly high transition risk, with roughly half of such individuals developing a psychotic disorder over several years. BLIPS that recur, or that involve seriously disorganizing or dangerous behavior, are associated with an especially high probability of later full psychosis.
 
Negative, disorganized, and cognitive symptoms
Prominent negative symptoms such as social withdrawal, anhedonia, and reduced motivation modestly increase transition risk, especially when combined with positive symptoms and functional decline. Disorganized communication and thought disorder, lower IQ, poorer verbal memory, and slowed information processing have each been linked to higher likelihood of transition within clinical high-risk samples.
 
Functioning and broader clinical picture
Lower global functioning at baseline (worse social, academic, or occupational performance) predicts higher transition risk, whereas better functioning appears somewhat protective. Early social dysfunction in adolescence, schizotypal personality traits, and movement abnormalities (e.g., subtle motor signs) has also been associated with elevated transition risk in high-risk cohorts.
 
Overall risk pattern
Meta-analytic data show that, taken together, these symptom and functioning markers identify a group whose probability of developing psychosis is much higher than in the general population, with cumulative transition risks around one-quarter within 3 years and continuing to rise over longer follow-up. However, even in high-risk clinics, most individuals do not make a full transition, which is why careful monitoring, psychosocial support, and targeted treatment of current symptoms are emphasized rather than assuming psychosis is inevitable.
 
References
 
Brasso, C., Giordano, B.,Badino, C., Bellino, S., Bozzatello, P., Montemagni, C. & Rocca, P. (2021, November 19). Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset. Diagnostics.
 
Carrion, R.E., Demmin, D., Auther, A.M., Mclaughlin, D., Olsen, R., Lencz, T., Correll, C. & Cornblatt, B.A. (2017, October 1). Duration of Attenuated Positive and Negative Symptoms in Individuals at Clinical High Risk: Associations with Risk of Conversion to Psychosis and Functional Outcome. Journal in Psychiatric Research.
 
De Pablo, G.S., Radua, J., Pereira, J., Bonoldi, I., Arienti, V., et al. (2021, July 14). 78(9):1-9. Probability of Transition to Psychosis in Individuals at Clinical High Risk.JAMA Psychiatry.
 
Keshavan, M.S., DeLisi, L.E. & Seidman, L.J. (2012, July 3). Early and Braodly Defined Psychosis Risk Mental States. Schizophrenia Research.
 
MOntermagni, C., Belliono, S., Bracale, N., Bozzatello, P. & Rocca, P. (2020, March 24). Models Predicting Psychosis in Patients with High Clinical Risk: A Systematic Review. Frontiers in Psychiatry.
 
Thompson, A., Marwaha, S. & Broome, M.R. (2018, January 2). At-Risk Mental State for Psychosis: Identification and Current Treatment Approaches. Advances. Cambridge University Press.